Pharma Industry Still Not At 'Tipping Point' In Adopting Continuous Manufacturing
Regulators and industry officials agree that despite efforts to spur development of continuous manufacturing, uptake has been slow globally. FDA still is on learning curve and acknowledges a knowledge gap around some of the higher order principles associated with continuous manufacturing.
You may also be interested in...
The oncology branch of the US FDA’s biologics center does not believe RTOR would speed application reviews.
A recent survey shows that pharmaceutical manufacturers are increasingly interested in adopting continuous manufacturing. Most respondents say they plan to use this mode of manufacturing for their new drugs.
The pharmaceutical industry may be approaching a "tipping point" with applications for continuous manufacturing, and successful applicants share secrets to the success they have achieved with FDA and other regulatory authorities around the world.